Volvo changes voting structure with share conversion

Martin Lundstedt President and CEO Volvo Group
Martin Lundstedt President and CEO - Volvo Group
0Comments

The number of votes in AB Volvo has been altered following the conversion of 175,000 Series A shares into an equal number of Series B shares. This change was facilitated by a provision allowing Series A shareholders to convert their shares, as introduced in the Articles of Association during the 2011 Annual General Meeting.

As of June 30, 2025, which marks the last trading day of the month, AB Volvo reports a total of 2,033,452,084 registered shares. These include 444,778,956 Series A shares and 1,588,673,128 Series B shares. Consequently, the total number of votes within the company now stands at 603,646,268.80 based on these registered shares.

“This information is information that AB Volvo (publ) is obliged to make public pursuant to the Financial Instruments Trading Act,” stated AB Volvo. The announcement was made available for publication at 13:00 CEST on June 30th.

For further inquiries regarding this development or other matters related to AB Volvo’s media relations efforts can be directed to Claes Eliasson at +46 76 553 7229 or via email at [email protected].

AB Volvo encourages those interested in more detailed updates to visit volvogroup.com and follow them on LinkedIn for regular news and insights.

The Volvo Group remains dedicated to advancing prosperity through its transport and infrastructure solutions portfolio. This includes offerings such as trucks, buses, construction equipment alongside power solutions for marine and industrial applications. The company also provides financing services aimed at enhancing customer productivity and uptime. Established in Gothenburg in 1927 with over a century-long history in sustainable transport innovation, it employs over 100 thousand people globally across nearly 190 markets. In fiscal year 2024 alone net sales reached SEK527 billion (EUR46 billion). Their stocks are publicly traded on Nasdaq Stockholm.



Related

Paul Hudson Chief Executive Officer Sanofi SA

Acoziborole receives key EU panel backing as single-dose treatment for sleeping sickness

Acoziborole Winthrop, a new oral treatment for sleeping sickness developed by the Drugs for Neglected Diseases initiative (DNDi) and Sanofi, has received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for…

Martin Lundstedt President and CEO at Volvo Group North America LLC Volvo Group North America LLC

Volvo announces updated share and vote count after series conversion

The number of votes in AB Volvo has changed following the conversion of 2,000,619 Series A shares into an equal number of Series B shares.

Paul Hudson Chief Executive Officer Sanofi SA

Sanofi and Regeneron’s Dupixent recommended for EU approval in young children with chronic urticaria

Sanofi and Regeneron have announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval of Dupixent (dupilumab) for children aged two to 11 years with…

Trending

The Weekly Newsletter

Sign-up for the Weekly Newsletter from EU Business Daily.